Benchmark Initiates Coverage on Flexion Therapeutics (FLXN)

Benchmark initiated coverage on shares of Flexion Therapeutics (NASDAQ:FLXN) in a report issued on Thursday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $39.00 price objective on the specialty pharmaceutical company’s stock.

Several other research firms have also issued reports on FLXN. Wells Fargo & Co reaffirmed a buy rating on shares of Flexion Therapeutics in a report on Saturday, May 5th. ValuEngine raised shares of Flexion Therapeutics from a hold rating to a buy rating in a report on Friday, April 27th. BidaskClub raised shares of Flexion Therapeutics from a strong sell rating to a sell rating in a report on Wednesday, February 28th. Finally, Zacks Investment Research raised shares of Flexion Therapeutics from a sell rating to a hold rating in a report on Friday, May 11th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock has an average rating of Buy and an average price target of $98.89.

NASDAQ FLXN opened at $25.85 on Thursday. The company has a current ratio of 15.57, a quick ratio of 15.47 and a debt-to-equity ratio of 0.67. Flexion Therapeutics has a 12-month low of $19.06 and a 12-month high of $32.25.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.33) by $0.23. The firm had revenue of $2.19 million during the quarter, compared to analysts’ expectations of $1.99 million. analysts predict that Flexion Therapeutics will post -4.74 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in FLXN. Schwab Charles Investment Management Inc. grew its holdings in shares of Flexion Therapeutics by 53.6% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 165,222 shares of the specialty pharmaceutical company’s stock valued at $4,138,000 after buying an additional 57,672 shares during the last quarter. Teacher Retirement System of Texas purchased a new stake in shares of Flexion Therapeutics during the fourth quarter valued at $245,000. Swiss National Bank grew its holdings in shares of Flexion Therapeutics by 33.4% during the fourth quarter. Swiss National Bank now owns 47,911 shares of the specialty pharmaceutical company’s stock valued at $1,200,000 after buying an additional 12,000 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Flexion Therapeutics by 1,024.1% during the fourth quarter. Wells Fargo & Company MN now owns 1,706,942 shares of the specialty pharmaceutical company’s stock valued at $42,742,000 after buying an additional 1,555,093 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Flexion Therapeutics by 17.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 25,369 shares of the specialty pharmaceutical company’s stock valued at $635,000 after buying an additional 3,794 shares during the last quarter. 96.86% of the stock is currently owned by hedge funds and other institutional investors.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply